Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
PURPOSE:This study aims to explore gene expression signatures and serum biomarkers to predict intrinsic chemoresistance in epithelial ovarian cancer (EOC). PATIENTS AND METHODS:Gene expression profiling data of 322 high-grade EOC cases between 2009 and 2010 in The Cancer Genome Atlas project (TCGA)...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3531383?pdf=render |
| _version_ | 1818478714104578048 |
|---|---|
| author | Yong Han Hao Huang Zhen Xiao Wei Zhang Yanfei Cao Like Qu Chengchao Shou |
| author_facet | Yong Han Hao Huang Zhen Xiao Wei Zhang Yanfei Cao Like Qu Chengchao Shou |
| author_sort | Yong Han |
| collection | DOAJ |
| description | PURPOSE:This study aims to explore gene expression signatures and serum biomarkers to predict intrinsic chemoresistance in epithelial ovarian cancer (EOC). PATIENTS AND METHODS:Gene expression profiling data of 322 high-grade EOC cases between 2009 and 2010 in The Cancer Genome Atlas project (TCGA) were used to develop and validate gene expression signatures that could discriminate different responses to first-line platinum/paclitaxel-based treatments. A gene regulation network was then built to further identify hub genes responsible for differential gene expression between the complete response (CR) group and the progressive disease (PD) group. Further, to find more robust serum biomarkers for clinical application, we integrated our gene signatures and gene signatures reported previously to identify secretory protein-encoding genes by searching the DAVID database. In the end, gene-drug interaction network was constructed by searching Comparative Toxicogenomics Database (CTD) and literature. RESULTS:A 349-gene predictive model and an 18-gene model independent of key clinical features with high accuracy were developed for prediction of chemoresistance in EOC. Among them, ten important hub genes and six critical signaling pathways were identified to have important implications in chemotherapeutic response. Further, ten potential serum biomarkers were identified for predicting chemoresistance in EOC. Finally, we suggested some drugs for individualized treatment. CONCLUSION:We have developed the predictive models and serum biomarkers for platinum/paclitaxel response and established the new approach to discover potential serum biomarkers from gene expression profiles. The potential drugs that target hub genes are also suggested. |
| first_indexed | 2024-12-10T09:51:28Z |
| format | Article |
| id | doaj.art-32826ba22ea54fceaed9187b064163c5 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T09:51:28Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-32826ba22ea54fceaed9187b064163c52022-12-22T01:53:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5274510.1371/journal.pone.0052745Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.Yong HanHao HuangZhen XiaoWei ZhangYanfei CaoLike QuChengchao ShouPURPOSE:This study aims to explore gene expression signatures and serum biomarkers to predict intrinsic chemoresistance in epithelial ovarian cancer (EOC). PATIENTS AND METHODS:Gene expression profiling data of 322 high-grade EOC cases between 2009 and 2010 in The Cancer Genome Atlas project (TCGA) were used to develop and validate gene expression signatures that could discriminate different responses to first-line platinum/paclitaxel-based treatments. A gene regulation network was then built to further identify hub genes responsible for differential gene expression between the complete response (CR) group and the progressive disease (PD) group. Further, to find more robust serum biomarkers for clinical application, we integrated our gene signatures and gene signatures reported previously to identify secretory protein-encoding genes by searching the DAVID database. In the end, gene-drug interaction network was constructed by searching Comparative Toxicogenomics Database (CTD) and literature. RESULTS:A 349-gene predictive model and an 18-gene model independent of key clinical features with high accuracy were developed for prediction of chemoresistance in EOC. Among them, ten important hub genes and six critical signaling pathways were identified to have important implications in chemotherapeutic response. Further, ten potential serum biomarkers were identified for predicting chemoresistance in EOC. Finally, we suggested some drugs for individualized treatment. CONCLUSION:We have developed the predictive models and serum biomarkers for platinum/paclitaxel response and established the new approach to discover potential serum biomarkers from gene expression profiles. The potential drugs that target hub genes are also suggested.http://europepmc.org/articles/PMC3531383?pdf=render |
| spellingShingle | Yong Han Hao Huang Zhen Xiao Wei Zhang Yanfei Cao Like Qu Chengchao Shou Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. PLoS ONE |
| title | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. |
| title_full | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. |
| title_fullStr | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. |
| title_full_unstemmed | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. |
| title_short | Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer. |
| title_sort | integrated analysis of gene expression profiles associated with response of platinum paclitaxel based treatment in epithelial ovarian cancer |
| url | http://europepmc.org/articles/PMC3531383?pdf=render |
| work_keys_str_mv | AT yonghan integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT haohuang integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT zhenxiao integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT weizhang integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT yanfeicao integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT likequ integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer AT chengchaoshou integratedanalysisofgeneexpressionprofilesassociatedwithresponseofplatinumpaclitaxelbasedtreatmentinepithelialovariancancer |